InVivo Therapeutics Holdings Corp(NVIV)- NASDAQ
  • Wed, Aug. 17, 10:59 AM
    | Wed, Aug. 17, 10:59 AM
  • Wed, Aug. 17, 9:22 AM
    | Wed, Aug. 17, 9:22 AM
  • Wed, Aug. 17, 9:14 AM
    • Thinly traded micro cap InVivo Therapeutics Holdings (NASDAQ:NVIV) is up 17% premarket on modest volume in response to its announcement that the fifth patient (out of eight in follow-up) in its INSPIRE study who was implanted with its Neuro-Spinal Scaffold has converted from a complete AIS A spinal cord injury to incomplete AIS B status between the two- and three-month evaluations, representing a 62.5% conversion rate.
    • According to the company, fewer than 16% of patients with complete thoracic spinal cord injuries experience an AIS grade improvement by six months post injury. In patients with high thoracic injury (T2 - T5), the conversion rate is less than 8%.
    • The fifth patient in INSPIRE had a T4-level injury.
    • The Neuro-Spinal Scaffold is a bioresorbable polymer scaffold that is designed to treat acute spinal cord injury. It is implanted at the injury site within a spinal cord contusion where it provides structural support to spinal tissue and a supportive matrix that facilitates endogenous tissue repair. It degrades over a period of several weeks.
    • Read now InVivo's Therapy On The Verge Of Becoming The De Facto Treatment For Spinal Cord Injury 
    | Wed, Aug. 17, 9:14 AM | 23 Comments
  • Thu, Aug. 11, 8:16 AM
    • InVivo Therapeutics Holdings (NASDAQ:NVIV) appoints Pamela Stahl to the newly created position of Chief Commercial Office effective September 14. Previously, she was with UnitedHealthcare as CEO, Community Health Plan of Wisconsin.
    | Thu, Aug. 11, 8:16 AM | 10 Comments
  • Thu, Aug. 4, 4:39 PM
    | Thu, Aug. 4, 4:39 PM
  • Fri, Jul. 22, 8:31 AM
    • OncoSec Medical (NASDAQ:ONCS) initiated with Buy rating and $6 (253% upside) price target by Rodman & Renshaw.
    • Invivo Therapeutics Holdings (NASDAQ:NVIV) initiated with Buy rating and $23.25 (254% upside) price target by Ladenburg Thalmann.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $105 (14% upside) price target by Baird.
    • Selecta Biosciences (Pending:SELB) initiated with Buy rating and $23 (64% upside) price target by Stifel Nicolaus.
    • Syros Pharmaceuticals (NASDAQ:SYRS) initiated with Neutral rating and $10 (11% downside risk) price target by H.C. Wainwright.
    • Voyager Therapeutics (NASDAQ:VYGR) initiated with Buy rating and $33 (161% upside) price target by Stifel Nicolaus.
    • AveXis (NASDAQ:AVXS) initiated with Market Perform rating by Wells Fargo.
    • Celgene (NASDAQ:CELG) initiated with Buy rating and $150 (40% upside) price target by Stifel Nicolaus.
    • ReWalk Robotics (NASDAQ:RWLK) initiated Overweight rating and $10 (49% upside) price target by Piper Jaffray.
    | Fri, Jul. 22, 8:31 AM
  • Tue, Jul. 12, 8:42 AM
    • Thinly traded micro cap InVivo Therapeutics Holdings (NASDAQ:NVIV) is up 6% premarket on light volume in response to its announcement that the 9th and 10th subjects have been implanted in its 20-subject Phase 3 clinical trial, INSPIRE, assessing the Neuro-Spinal Scaffold in patients with acute spinal cord injury.
    • The 10th patient died from a stroke several days post-implantation. The cause of death was determined to be unrelated to the Neuro-Spinal Scaffold.
    • The primary endpoint is the proportion of patients who achieve an improvement of at least one AIS grade level at month 6. According to ClinicalTrials.gov, the estimated study completion date is June 2017.
    • The Neuro-Spinal Scaffold is a bioresorbable polymer scaffold that is designed to treat acute spinal cord injury. It is implanted at the injury site within a spinal cord contusion where it provides structural support to spinal tissue and a supportive matrix that facilitates endogenous tissue repair. It degrades over a period of several weeks.
    | Tue, Jul. 12, 8:42 AM | 3 Comments
  • Fri, May 6, 4:35 PM
    | Fri, May 6, 4:35 PM
  • Tue, Apr. 26, 12:46 PM
    | Tue, Apr. 26, 12:46 PM | 2 Comments
  • Tue, Apr. 26, 11:27 AM
    • InVivo Therapeutics (NVIV +13%) heads north on almost double normal volume in response to its announcement of positive results in its 20-subject Phase 3 INSPIRE study assessing its Neuro-Spinal Scaffold in patients with complete (AIS A) thoracic spinal cord injuries at the time of enrollment.
    • A fourth patient (out of a total of six) has converted from AIS A status (complete spinal cord injury) to AIS B status (incomplete), implying a 67% response rate. The primary endpoint of the trial is the proportion of patients who experience an improvement of at least one AIS grade by month six. The Objective Performance Criterion (OPC), a measure of success for INSPIRE, is a minimum conversion rate of 25%, significantly better than the historical rate of ~16%.
    • The American Spinal Injury Association (ASIA) ranks spinal cord injury in five classes: A: Complete (no sensory or motor function); B: Sensory Incomplete (sensory but no motor function below the neurological level; C: Motor Incomplete (motor function preserved below the neurological level; D: Motor Incomplete (higher muscle function than "C"); E: Normal.
    • According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is June 2017.
    • The Neuro-Spinal Scaffold is a bioresorbable polymer scaffold that is designed to treat acute spinal cord injury. It is implanted at the injury site within a spinal cord contusion where it provides structural support to spinal tissue and a supportive matrix that facilitates endogenous tissue repair. It degrades over a period of several weeks.
    | Tue, Apr. 26, 11:27 AM | 7 Comments
  • Tue, Apr. 26, 9:16 AM
    | Tue, Apr. 26, 9:16 AM
  • Tue, Mar. 15, 12:49 PM
    | Tue, Mar. 15, 12:49 PM
  • Tue, Mar. 15, 9:28 AM
    • InVivo Therapeutics (NASDAQ:NVIV) is down 9% premarket on light volume in response to its public offering of 3,733,333 units at $7.50 per unit. Each unit consists of one share of common stock and 1/2 of a warrant to buy one share of common at $10.00 per share.
    • Underwriters over-allotment is an additional 560K shares of stock and/or warrants to purchase up to 280K shares. Closing date is March 18.
    | Tue, Mar. 15, 9:28 AM | 4 Comments
  • Mon, Mar. 14, 5:43 PM
    | Mon, Mar. 14, 5:43 PM | 2 Comments
  • Mon, Mar. 14, 4:44 PM
    • InVivo Therapeutics (NASDAQ:NVIV) announces plans to float a public offering of stock and warrants, packaged as units. Prices, volumes and terms have yet to be announced. Net proceeds will fund ongoing clinical trials and general corporate purposes.
    • Shares are down 9% after hours on light volume.
    | Mon, Mar. 14, 4:44 PM | 7 Comments
  • Mon, Mar. 7, 9:11 AM
    | Mon, Mar. 7, 9:11 AM | 1 Comment